Compare MXCT & QMLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | QMLS |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.8M | 127.1M |
| IPO Year | 2021 | 2025 |
| Metric | MXCT | QMLS |
|---|---|---|
| Price | $1.38 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $4.11 | ★ $10.33 |
| AVG Volume (30 Days) | ★ 1.4M | 236.4K |
| Earning Date | 11-10-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,026,000.00 | N/A |
| Revenue This Year | $4.77 | $371.05 |
| Revenue Next Year | $10.06 | $427.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $2.08 |
| 52 Week High | $1.80 | $14.82 |
| Indicator | MXCT | QMLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 28.98 |
| Support Level | $1.02 | N/A |
| Resistance Level | $1.54 | $3.91 |
| Average True Range (ATR) | 0.14 | 0.49 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 70.41 | 3.22 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
QumulusAI Inc is a cloud infrastructure company engaged in the rapid deployment of graphics processing unit (GPU)-powered solutions for artificial intelligence (AI) applications, serving a critical market that is often overlooked by large-scale cloud providers (hyperscalers), which operate massive, standardized computing infrastructures serving the immense enterprises. The platform delivers flexible, competitively priced, and customizable solutions for underserved small- and mid-market customers, including machine learning teams, AI infrastructure startups, and research institutions, and also supports the scale and complexity requirements of large enterprises. Its products are B300 SXM6, B200 SXM, RTX Pro 6000, H200 SXM, and Others. Its solutions are Enterprise, Research, and AI Startups.